摘要
目的探讨血清高尔基体糖蛋白73(Golgi protein-73;GP73)对肝细胞癌及胆管细胞癌的诊断价值;方法采用双抗体夹心酶联免疫(ELISA)定量测定方法,检测60例肝细胞癌患者(Hepatocellular carcinoma,HCC)、50例胆管细胞癌患者(intrahepatic cholangiocarcinoma,ICC)以及30例健康献血者血清标本中高尔基体糖蛋白(Golgiglycoprotein,GP37)的浓度。结果血清GP37在HCC组的表达明显高于ICC组以及健康组(P<0.05);GP37在诊断HCC的敏感度和准确度均要优于AFP(P<0.05),二者特异度的差异无统计学意义;GP37在诊断HCC的敏感度、特异度以及准确度均高于诊断ICC。结论 GP37有可能成为诊断和鉴别诊断HCC和ICC新的临床肿瘤标记物。
Objective To investigate the value of serum Golgi protein-73(GP73)in the diagnosis of hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(ICC).Methods Serum levels of GP73 were detected by ELISA in 60 HCC patients,50 ICC patients and 30 healthy blood donors.Results Serum levels of GP73 in HCC patients were significantly higher than those in ICC patients and healthy subjects(P<0.05).Furthermore,GP37 detection was more sensitive and accurate than AFP detection for diagnosing HCC(P<0.05).There was nosignificant difference between the two groups.The sensitivity,specificity and accuracy of GP37 detection in diagnosing HCC were higher than those in diagnosing ICC.Conclusion GP37 may be a new clinical tumor marker for the diagnosis and differential diagnosis of HCC and ICC.
出处
《南昌大学学报（医学版）》
CAS
2017年第1期19-22,共4页
Journal of Nanchang University：Medical Sciences
基金
江西省卫生计生委科技计划(20155289)
关键词
高尔基体糖蛋白73
肝细胞肝癌
胆管细胞癌
Golgi glycoprotein 73
hepatocellular carcinoma
intrahepatic cholangiocarcinoma
